Treatment at Academic Facilities Is Associated With Improved Survival in Late-Stage Colonic Neuroendocrine Tumors

Nicholas R Suss1, Sara Abou Azar1, Kelvin Memeh2

  • 1Department of Surgery, University of Chicago Medicine, Chicago, Illinois.

PubMed
Abstract

Insights

Treatment at academic facilities improves survival for late-stage colonic neuroendocrine tumors (NETs). Further research is needed to understand these differences and improve care for all NET patients.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Epidemiology

Background:

  • Colonic neuroendocrine tumors (NETs) are rare and require complex management.
  • The impact of treatment facility type on survival for colonic NETs is not well-established.

Purpose of the Study:

  • To determine if treatment facility type (academic vs. non-academic) influences overall survival (OS) in patients with colonic NETs.
  • To identify factors associated with mortality in colonic NET patients.

Main Methods:

  • Analysis of the National Cancer Database (2004-2021) for patients with stages I-IV colonic NETs undergoing surgery.
  • Comparison of outcomes between academic and non-academic treatment facilities using Cox and Kaplan-Meier models.

Main Results:

  • Patients treated at academic facilities had a decreased risk of mortality (HR 0.89) and improved median OS (161.1 vs. 146.6 months).
  • A survival benefit was observed for late-stage (III and IV) colonic NETs treated at academic facilities, but not for early-stage (I and II) disease.
  • Younger age, metropolitan residence, and longer travel distance were associated with treatment at academic facilities, which were also more likely to perform complex resections.

Conclusions:

  • Treatment at academic facilities is associated with improved survival for patients with late-stage colonic NETs.
  • Understanding the reasons for this survival difference is crucial for improving care and bridging gaps in treatment for colonic NET patients.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...